Distinguished in Renal Cell Carcinoma (RCC)

Simon A. Chowdhury

King's And St. Thomas' Hospitals And Sarah Cannon Research Institute, 
London, ENG, GB 
Distinguished in Renal Cell Carcinoma (RCC)
King's And St. Thomas' Hospitals And Sarah Cannon Research Institute, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Simon Chowdhury practices in London, United Kingdom. Mr. Chowdhury is rated as a Distinguished expert by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Orchiectomy, and Nephrectomy.

His clinical research consists of co-authoring 184 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 28 articles in the study of Renal Cell Carcinoma (RCC).

Gender
Male

Locations

King's And St. Thomas' Hospitals And Sarah Cannon Research Institute, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Drugs: Enzalutamide, Non-Steroidal Anti Androgen, Luteinizing Hormone Releasing Hormone Analog or Surgical Castration
Study Phase: Phase 3
A Phase 2, Open-Label, Single-Arm Study of BGB-290 (BGB-290) for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Homologous Recombination Deficiency (HRD)
A Phase 2, Open-Label, Single-Arm Study of BGB-290 (BGB-290) for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Homologous Recombination Deficiency (HRD)
Enrollment Status: Terminated
Publish Date: November 17, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

184 Total Publications

Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials.
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials.
Journal: JAMA network open
Published: August 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Chowdhury's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile